Comparison of insulin aspart with buffered regular insulin and insulin lispro in continuous subcutaneous insulin infusion: a randomized study in type 1 diabetesBruce Bode
Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
Diabetes Care 25:439-44. 2002
..To compare the safety and efficacy of insulin aspart (IAsp), buffered regular insulin (BR), and insulin lispro administered by continuous subcutaneous insulin infusion (CSII) in patients with type 1 diabetes...
- Patient perception and use of an insulin injector/glucose monitor combined device
Bruce Bode
Atlanta Diabetes Associates, 77 Collier Road NW, Suite 2080, Atlanta, GA 30309, USA
Diabetes Educ 30:301-9. 2004
..This clinical trial assessed patient preference, satisfaction, and use of an insulin injector/glucose monitor combination device versus syringes and a separate glucose monitor...
Incretin-based therapies: review of the outpatient literature with implications for use in the hospital and after dischargeBruce Bode
Atlanta Diabetes Associates, Atlanta, GA 30309, USA
Hosp Pract (1995) 37:7-21. 2009
..This review examines the challenges to achieving glycemic control in the hospital setting and summarizes clinical data on the efficacy and safety of incretin-based therapies in their use in the hospital and after discharge...
- Liraglutide: a review of the first once-daily GLP-1 receptor agonist
Bruce Bode
Atlanta Diabetes Associates, 77 Collier Rd, Ste 2080, Atlanta, GA 30309, USA
Am J Manag Care 17:S59-70. 2011
..The guidelines prefer GLP-1 agonists over DPP-4 inhibitors because of their actions that promote weight loss and their somewhat greater effectiveness in reducing postprandial glucose excursions...
- The suboptimal roadmap to the intensive therapy target
Paul Davidson
Atlanta Diabetes Associates, Atlanta, Georgia 30309, USA
Diabetes Technol Ther 6:17-9. 2004
- Alarms based on real-time sensor glucose values alert patients to hypo- and hyperglycemia: the guardian continuous monitoring system
Bruce Bode
Atlanta Diabetes Associates, Atlanta, Georgia, USA
Diabetes Technol Ther 6:105-13. 2004
....
- An overview of the pharmacokinetics, efficacy and safety of liraglutide
Bruce Bode
Atlanta Diabetes Associates, 77 Collier Rd, Suite 2080, Atlanta, GA 30309, USA
Diabetes Res Clin Pract 97:27-42. 2012
..The aim of this review is to assess the pharmacokinetics, efficacy and safety of the phase 3 data...
- Evaluation of a continuous glucose monitoring system for home-use conditions
Bruce Bode
Atlanta Diabetes Associates, USA
Manag Care 17:40-5. 2008
..To evaluate the safety and effectiveness of the FreeStyle Navigator Continuous Glucose Monitoring System when used by adult patients with type 1 or 2 diabetes requiring insulin in the home environment...
- JDRF randomized clinical trial to assess the efficacy of real-time continuous glucose monitoring in the management of type 1 diabetes: research design and methods
William V Tamborlane
Diabetes Technol Ther 10:310-21. 2008
..RESULTS: Recruitment for the study was completed on December 15, 2007. CONCLUSION: Results of this clinical trial should help establish whether or not current RT-CGM devices are beneficial to patients with T1D...
- Initiating insulin therapy in type 2 Diabetes: a comparison of biphasic and basal insulin analogs
Philip Raskin
Department of Internal Medicine, Southwestern Medical Center at Dallas, Dallas, TX 75390 8858, USA
Diabetes Care 28:260-5. 2005
..Safety and efficacy of biphasic insulin aspart 70/30 (BIAsp 70/30, prebreakfast and presupper) were compared with once-daily insulin glargine in type 2 diabetic subjects inadequately controlled on oral antidiabetic drugs (OADs)...
- Use of the Continuous Glucose Monitoring System to guide therapy in patients with insulin-treated diabetes: a randomized controlled trial
Robert Tanenberg
Brody School of Medicine, Greenville, NC, USA
Mayo Clin Proc 79:1521-6. 2004
..1 minutes per event, P = .009). CONCLUSION: Use of the CGMS to guide therapy adjustments in patients with insulin-treated diabetes reduces the duration of hypoglycemia compared with therapy adjustments guided by SMBG values alone...
- Oral insulin therapy to prevent progression of immune-mediated (type 1) diabetes
Berrin Ergun-Longmire
Division of Pediatric Endocrinology, New York-Presbyterian Hospital, Weill Medical College of Cornell University, New York, NY, USA
Ann N Y Acad Sci 1029:260-77. 2004
..If confirmed, these findings suggest that diabetic patients over age 20 years with ICA evidence of late-onset immune-mediated diabetes should be considered for oral insulin at 1 mg/day to better retain endogenous insulin secretion...
